BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway

Background: Sorafenib is an oral multi-kinase inhibitor that inhibits hepatocellular carcinoma (HCC) via the Ras/Raf/MAPK pathway. However, sorafenib loses effectiveness because most tumors acquire drug resistance over time. As the PI3K/AKT/mTOR signaling pathway is also activated abnormally in HCC,...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Transl Res
Hlavní autoři: Li, Amin, Zhang, Rongbo, Zhang, Yinci, Liu, Xueke, Wang, Ruikai, Liu, Jiachang, Liu, Xinkuang, Xie, Yinghai, Cao, Weiya, Xu, Ruyue, Ma, Yongfang, Cai, Wenpeng, Wu, Binquan, Cai, Shuyu, Tang, Xiaolong
Médium: Artigo
Jazyk:Inglês
Vydáno: e-Century Publishing Corporation 2019
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6789287/
https://ncbi.nlm.nih.gov/pubmed/31632530
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky